Welcome to a new partnership for life

Ceva Animal Health has recently launched CARDALIS®, a treatment for canine congestive heart failure caused by chronic degenerative valvular disease. CARDALIS® contains both benazepril and spironolactone in a single palatable tablet and is designed to be given as part of first-line therapy as soon as heart failure is diagnosed.

What are the benefits in giving both active ingredients together? The answer lies in the RAAS system, which involves the production of both angiotensin II and aldosterone, and the concept of dual blockade.

ACE Inhibitors, such as benazepril, inhibit the production of angiotensin II, which are responsible for a number of harmful effects, including vasoconstriction (narrowing of the blood vessels). However, despite these benefits, aldosterone levels can continue to rise1,2. Aldosterone stimulates fluid reabsorption in the kidneys but, more importantly, also promotes cardiac remodelling/ fibrosis3. This causes the heart muscle to become stiffened, reducing its ability to contract.

Trial work in dogs with mitral valve disease has shown that, when used as part of first-line therapy, the combination of benazepril and spironolactone (dual blockade) versus benazepril alone results in an 89% reduction in the risk of mortality, quicker improvement in cough/ activity levels and a slower deterioration of heart sounds and appetite4.

CARDALIS® contains both benazepril and spironolactone and therefore provides dual RAAS blockade in a single tablet. The tablets are small, beef flavoured and designed to be given once daily with food.

www.ceva.com.au

 

References

1. Bernay, F. et al. (2010), JVIM, 24(2), 331-341

2. Atkins, C. and Haggstrom, J. (2012), J Vet Cardiol, 14, 165-184

3. Ovaert, P. et al. (2010), JVPT, 33(2), 109-117.

4. Data on file